BPC-157 Side Effects: Safety Signals and Warnings
BPC-157 safety concerns are compound-specific. The main listed side effects are No significant toxicity reported at tested doses in several rodent studies, No genotoxicity or mutagenicity identified in preclinical safety assessments, and Human adverse-event frequency cannot be estimated from the available evidence. The main warning signals are Not FDA-approved for any medical condition; classified as a research chemical, FDA cites immunogenicity, peptide-related impurities, and insufficient human safety information as compounding concerns, and Virtually all evidence is from a single research group at the University of Zagreb - independent replication is limited.
BPC-157 Field Guide
A plain-English guide to the claims people make about BPC-157, what the evidence actually says, and which uncertainties matter most.
Built as a field reference: common claims first, evidence quality second, then safety, regulatory context, and the primary-source map.
Direct Answer
BPC-157 has an unusually large preclinical healing literature, but no completed human efficacy trial or approved formulation. The 2026 independent rat tendon study was less convincing for BPC-157 than for TB-500 and did not show a benefit from combining them. It is useful for studying repair mechanisms, not a clinically validated treatment.
- Evidence grade
- Level B
- Research status
- Phase 2
- Category
- Healing & Recovery
- Evidence context
- Preclinical study of tendon, gastrointestinal, and tissue-repair mechanisms
Reported Side Effects
- No significant toxicity reported at tested doses in several rodent studies
- No genotoxicity or mutagenicity identified in preclinical safety assessments
- Human adverse-event frequency cannot be estimated from the available evidence
- No completed, published human safety trial establishes short- or long-term safety
Warnings
- Not FDA-approved for any medical condition; classified as a research chemical
- FDA cites immunogenicity, peptide-related impurities, and insufficient human safety information as compounding concerns
- Virtually all evidence is from a single research group at the University of Zagreb - independent replication is limited
- Long-term human safety is completely unknown
- May interact with drugs that affect the nitric oxide system or dopaminergic signaling
- Theoretical oncological concern: pro-angiogenic peptides could theoretically accelerate growth of occult tumors, though this has not been observed in rodent studies
Known or Plausible Interactions
- NSAIDs (may counteract NSAID-induced GI damage in animals; clinical significance unknown)
- Alcohol (reversed ethanol-induced gastric lesions in rat studies)
- Dopamine agonists/antagonists (BPC-157 modulates dopaminergic pathways in rodent CNS studies)
- L-NAME and other NOS inhibitors (partial attenuation of BPC-157's protective effects in some models)
Regulatory Context
BPC-157 is not FDA-approved for any indication. FDA has identified safety concerns for compounded BPC-157, including immunogenicity, peptide-related impurities, and insufficient information to determine whether it would harm humans. WADA names BPC-157 in section S0 of the 2026 Prohibited List, so it is prohibited at all times in tested sport.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Phase 2 |
| Best supported outcomes | Tendon & Ligament Healing (Level B), Gut Health & Protection (Level B), Muscle Recovery (Level C), and Bone Healing (Level C) |
| Primary citation count | 10 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of BPC-157?
BPC-157 safety concerns are compound-specific. The main listed side effects are No significant toxicity reported at tested doses in several rodent studies, No genotoxicity or mutagenicity identified in preclinical safety assessments, and Human adverse-event frequency cannot be estimated from the available evidence. The main warning signals are Not FDA-approved for any medical condition; classified as a research chemical, FDA cites immunogenicity, peptide-related impurities, and insufficient human safety information as compounding concerns, and Virtually all evidence is from a single research group at the University of Zagreb - independent replication is limited.
What is the evidence level for BPC-157?
BPC-157 is rated Level B. Its current research status is Phase 2.
What is BPC-157 best known for?
Preclinical study of tendon, gastrointestinal, and tissue-repair mechanisms.
Where can I read the full BPC-157 evidence review?
The full evidence review is available at https://examinepeptides.com/library/bpc-157.
Related Guides
How to Cite This Page
ExaminePeptides. "BPC-157 Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/bpc-157-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.